Azusa Takahashi-Nakaguchi

Oct 20, 2023 | mdpi.com | Keiko Nakano |Michiyo Okamoto |Azusa Takahashi-Nakaguchi |Kaname Sasamoto

1. IntroductionThe threat of antimicrobial resistance (AMR) has progressed in parallel with the COVID-19 pandemic caused by the SARS-CoV-2 virus [1]. These resistant pathogens include drug-resistant Candida [1,2,3]. In recent years, drug-resistant Candida species other than Candida albicans, called non-albicans Candida, have become more common, especially Candida glabrata. Therefore, the development of new antifungal agents against them is urgently needed [4,5,6].

Feb 10, 2023 | mdpi.com | Keiko Nakano |Michiyo Okamoto |Azusa Takahashi-Nakaguchi |Kaname Sasamoto

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.